Future research should assess the impact of baseline ferritin levels and bone marrow blast percentages on ESA response/failure, by using multivariate analyses that include data from large patient populations in LR-MDS and consider relevant prognostic factors such as serum EPO levels, baseline hemoglobin, and transfusion dependence status. This evidence concerns the gene EPO and myelodysplastic syndrome.